Lopes Roberto I, Lorenzo Armando
Division of Urology, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Surgery, University of Toronto, Toronto, ON, Canada.
F1000Res. 2017 May 12;6:670. doi: 10.12688/f1000research.10760.1. eCollection 2017.
The objective of this article is to present an overview of recent trends in the management of Wilms' tumor. With improved survival rates in the past few decades, critical long-term adverse therapy effects (such as renal insufficiency, secondary malignancies, and heart failure) and prevention measures (i.e. nephron-sparing surgery and minimizing the use of radiotherapy) have gained worldwide attention. Specific disease biomarkers that could help stratify high-risk from low-risk patients, and therefore fine-tune management, are in great demand. Ultimately, we aim to enhance clinical outcomes and maintain or improve current survival rates while avoiding undesirable treatment side effects and minimizing the exposure and intensity of chemotherapy and radiotherapy.
本文的目的是概述肾母细胞瘤管理的近期趋势。在过去几十年中，随着生存率的提高，关键的长期不良治疗效果（如肾功能不全、继发性恶性肿瘤和心力衰竭）以及预防措施（即保留肾单位手术和尽量减少放疗的使用）已引起全球关注。人们迫切需要能够帮助区分高危和低危患者从而优化管理的特定疾病生物标志物。最终，我们的目标是提高临床疗效，维持或提高当前的生存率，同时避免不良治疗副作用，并尽量减少化疗和放疗的暴露及强度。
